Zimmer Biomet (NYSE:ZBH) Upgraded by Wall Street Zen to “Buy” Rating

Zimmer Biomet (NYSE:ZBH) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Other equities analysts have also issued reports about the company. Barclays reduced their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Leerink Partners started coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. BMO Capital Markets started coverage on shares of Zimmer Biomet in a report on Wednesday, July 8th. They issued a “market perform” rating and a $95.00 price objective for the company. Citigroup reduced their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Finally, Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $91.35 on Friday. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a fifty day moving average of $87.90 and a 200-day moving average of $89.81. The company has a market capitalization of $17.67 billion, a P/E ratio of 23.73, a P/E/G ratio of 2.64 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities research analysts predict that Zimmer Biomet will post 8.48 EPS for the current fiscal year.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.28% of the stock is currently owned by company insiders.

Institutional Trading of Zimmer Biomet

Several large investors have recently modified their holdings of ZBH. PNC Financial Services Group Inc. raised its holdings in shares of Zimmer Biomet by 9.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after acquiring an additional 13,883 shares in the last quarter. Douglas Lane & Associates LLC boosted its holdings in Zimmer Biomet by 6.7% in the fourth quarter. Douglas Lane & Associates LLC now owns 460,178 shares of the medical equipment provider’s stock valued at $41,379,000 after acquiring an additional 28,818 shares in the last quarter. Morningstar Investment Management LLC increased its position in Zimmer Biomet by 235.4% during the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock valued at $5,204,000 after purchasing an additional 40,610 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Zimmer Biomet by 257.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after purchasing an additional 24,748 shares during the period. Finally, CIBC Asset Management Inc raised its holdings in Zimmer Biomet by 67.6% in the 4th quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock worth $4,183,000 after purchasing an additional 18,769 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.